U.S. Industrial REITs Stock News

Recent share performance and business mix Markel Group (MKL) has recently drawn attention after a one-month return of about a 4% decline and a past three-month return of roughly an 11% decline, contrasting with a positive one-year total return of 13.1%. The company operates across insurance and a range of industrial and consumer businesses. Markel Insurance generates about US$10.3b of revenue, alongside contributions from the Industrial, Consumer and Other, Financial, and Corporate...

Keybanc analyst Aleksey Yefremov recently shifted his rating on Avient (AVNT) from Overweight to Sector Weight, a change that puts fresh attention on how the stock compares with its peers. See our latest analysis for Avient. Avient shares recently pulled back, with a 1 day share price return of a 3.65% decline and a 30 day share price return of a 4.15% decline. However, the 1 year total shareholder return of 21.30% and the year to date share price return of 10.60% suggest momentum has...

Lindsay (LNN) is back in focus after reporting quarterly results that missed analyst expectations, with softer demand in both Irrigation and Infrastructure, weaker operating margins, and management flagging limited near term growth catalysts. See our latest analysis for Lindsay. The weak quarter has been followed by a sharp reset in expectations, with a 1 month share price return showing a decline of 20.51% and a 1 year total shareholder return showing a loss of 12.90%, pointing to fading...

EnerSys (ENS) has drawn attention after announcing the closure of its legacy lead-acid battery plant in Tijuana, with production shifting to its Thin Plate Pure Lead facility in Springfield, Missouri. See our latest analysis for EnerSys. The stock’s recent 14.32% 1 month share price return and 17.66% year to date share price return suggest momentum has been building, while the 120.67% 1 year total shareholder return points to stronger gains over a longer stretch. If you are looking beyond...

MARA Holdings (MARA) is shaking up its business model after selling 15,133 Bitcoin for about US$1.1b, cutting its workforce by 15%, and retiring roughly 30% of its convertible debt. See our latest analysis for MARA Holdings. The latest restructuring news has arrived alongside a 1 day share price return of 8.33% and a 7 day share price return of 11.74%. However, the 1 year total shareholder return of 22.65% and 5 year total shareholder return of 82.60% indicate that longer term momentum has...

In March 2026, Elastic announced that Elastic Cloud Hosted on AWS GovCloud (US) achieved FedRAMP High authorization, enabling U.S. federal agencies to run sensitive, high-impact workloads for security, Zero Trust, and AI-powered mission applications on a standardized, rigorously vetted cloud platform. Elastic also introduced Elastic Workflows as a native automation layer inside Elastic Security, aiming to replace standalone SOAR tools by combining scripted playbooks with AI agents that act...

In March 2026, Brightstar Lottery PLC entered into new senior secured multicurrency revolving credit facilities totaling US$650 million and €1,000 million, aligning covenants across its major debt agreements and refinancing older facilities to support general corporate purposes. By locking in a five-year funding backstop with terms linked to its public credit ratings, Brightstar Lottery has materially expanded its financial flexibility and tightened the link between its borrowing costs and...

Valley National Bancorp (VLY) is back in focus after JPMorgan reiterated its Overweight rating while trimming its price target, as investors weigh the bank’s 25 million share buyback and broader capital plans. See our latest analysis for Valley National Bancorp. That reassessment has cooled very short term enthusiasm, with a 1 day share price return of a 0.16% decline, but the 7 day share price return of 4.37% and 1 year total shareholder return of 59.59% suggest momentum has been building...

Relay Therapeutics recently announced that initial clinical and preclinical data for its PI3Kα inhibitor zovegalisib in vascular anomalies will be presented at the International Society for the Study of Vascular Anomalies World Congress 2026 in May, based on results that supported advancing the regimen into the ongoing Phase 3 ReDiscover-2 trial. By aiming a mutant-selective PI3Kα inhibitor at both PIK3CA-driven vascular anomalies and certain breast cancers, Relay Therapeutics is linking a...

In late March 2026, Johnson & Johnson reported 52-week Phase 3 data showing its oral peptide ICOTYDE maintained high complete skin clearance rates and a consistent safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, while Royalty Pharma announced a US$500 million R&D co-funding agreement to advance JNJ-4804 for autoimmune diseases. These developments highlight Johnson & Johnson’s push to build a differentiated immunology portfolio, pairing late-stage oral...

The latest move for Nuvation Bio (NUVB) centers on Europe, where the European Medicines Agency has validated the Marketing Authorisation Application for taletrectinib in advanced ROS1-positive non-small cell lung cancer. See our latest analysis for Nuvation Bio. The EMA validation comes shortly after Nuvation Bio secured global rights to safusidenib in Japan, against a backdrop of a 7 day share price return of 8.89% but a 90 day share price return decline of 48.06%, while the 1 year total...

Centene Corporation recently announced that, effective March 18, 2026, long-time finance executive and CPA Theodore Pienkos became Corporate Controller and Chief Accounting Officer, while prior controller Kate Casso moved into a new Senior Vice President role overseeing finance operations and innovation. These leadership shifts arrive as Centene faces pressure from elevated Medicaid and ACA marketplace medical costs and the company’s decision to withdraw its 2025 guidance, placing extra...

In its recently reported second quarter of fiscal 2026, AutoZone posted earnings of US$27.63 per share with net sales up 8.2% year over year, while adding 64 new stores across the U.S., Mexico, and Brazil to reach 7,774 locations worldwide. Alongside these results, the company saw gross profit improve but operating profit ease by 1.2% and inventory grow 13.1%, reflecting the cost and complexity of its expansion and inflationary pressures. With this expansion-driven inventory build and...

Why Gartner’s recognition matters for Manhattan Associates (MANH) Manhattan Associates (MANH) was again named a Leader in Gartner's Magic Quadrant for Transportation Management Systems, its eighth consecutive appearance, after launching AI Agents within its cloud-native Manhattan Active solutions for real-time supply chain operations. See our latest analysis for Manhattan Associates. Despite the Gartner recognition and AI product launches, the 30 day share price return of 11.73% and year to...

CSG Systems International (NasdaqGS:CSGS) has entered a significant partnership with ePLDT Group to support digital solutions and enterprise services in the Philippines. The collaboration extends CSG’s platform solutions into a new Southeast Asian market within the region’s information and communications technology sector. The agreement focuses on helping enterprise clients streamline and manage their digital offerings across a growing set of services. CSG Systems International, known for...

Why earnings revisions matter for McKesson (MCK) right now Recent upward revisions to McKesson (MCK) earnings estimates, together with its record of surpassing consensus EPS in recent quarters, have put fresh attention on how the company’s pharmaceutical distribution revenue story is shaping up. See our latest analysis for McKesson. McKesson’s share price has moved to US$884.28, with a 1-day share price return of 1.37% and a 90-day share price return of 6.99%. Its 1-year total shareholder...

Diodes (DIOD) has expanded its PowerDI8080-5 N-channel MOSFET line, targeting automotive and industrial uses where efficiency, compact footprints, and reliability in electric and hybrid vehicles are central design priorities for engineers. See our latest analysis for Diodes. That product launch lands against a share price that has moved to $68.58, with a 30-day share price return of 10.81% and a 1-year total shareholder return of 86.97%. However, 3 and 5-year total shareholder returns remain...

In Q4 2025, Halozyme Therapeutics reported EPS of US$0.24 and revenue of US$451.77 million, exceeding revenue expectations but falling short on earnings, while reiterating its 2026 revenue guidance, updating 2025 guidance, and appointing David Ramsay as interim CFO on March 23, 2026. Despite the mixed quarter, analysts highlighted Halozyme’s growing royalty revenues and expanding ENHANZE partnerships as key drivers behind their more optimistic outlooks. With stronger revenue performance and...

In recent months, Tenet Healthcare reported quarterly revenue of US$5.53 billion and earnings per share of US$4.70, both ahead of consensus estimates, while analysts have become more positive on its earnings outlook. An orderly transition in Tenet’s senior finance leadership, paired with consistent earnings outperformance, highlights how its financial reporting function underpins investor confidence. We’ll now examine how Tenet’s continued earnings outperformance shapes its investment...

L3Harris Technologies recently supported the historic Artemis II crewed mission to the moon by supplying more than 100 propulsion, thruster, avionics and communications elements, including RS-25 and RL10 engines, in-space course-correction thrusters, 40 advanced avionics systems and the Orion audio system. This extensive role in a high-profile lunar mission, alongside its work on infrared tracking satellites and resilient multi-orbit communications, highlights L3Harris’s deep integration in...

What EPR Properties’ recent returns say about investor sentiment EPR Properties (EPR) has drawn fresh attention after a mixed run in its recent returns, with the share price showing a 1.7% move over the past day and a 3.8% gain over the past week. Over the past month, the stock shows an 11% decline, while the past 3 months are roughly flat. Against that backdrop, investors are weighing EPR’s US$713.961 million in revenue and US$250.792 million in net income alongside its current value score...

In late March 2026, Cimpress plc announced a new share repurchase program authorizing the company to buy back up to US$200,000,000 of its shares following the expiry of a prior plan on March 25, 2026. This fresh authorization highlights Cimpress’ willingness to return capital to shareholders, potentially altering how investors assess its capital allocation and balance-sheet priorities. We’ll now examine how this new US$200,000,000 share repurchase authorization might reshape Cimpress’...

Structure Therapeutics recently reported encouraging Phase 2 trial results for its oral obesity drug candidate aleniglipron, coinciding with renewed attention on GLP-1 weight-loss treatments following US FDA approval of a competing therapy from Eli Lilly. The combination of promising oral obesity data and rising institutional interest highlights how Structure Therapeutics has become more central to the fast-evolving obesity treatment landscape. We’ll now examine how the promising Phase 2...

On 28 March 2026, the European Space Agency announced that Rocket Lab’s Electron rocket successfully launched the “Daughter Of The Stars” mission from New Zealand, placing ESA’s first two “Celeste” low Earth orbit navigation demonstration satellites into a 510 km orbit. This mission, which maintained Rocket Lab’s 100% success record for national space programs and marked its 6th launch of 2026 and 85th overall, underscores the company’s growing role as a reliable commercial provider for...